2-[(4S)-6-(4-Chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide(CAS: 1260907-17-2)

The compound is a crystalline solid with a molecular weight of approximately 474.24 g/mol. It has a low solubility in water but is more soluble in organic solvents. Chemically, it is stable under normal conditions but may react with strong acids or bases. It does not readily undergo substitution reactions but can participate in conjugate addition reactions.

This compound is typically synthesized via a multistep process involving the formation of a triazole ring followed by amidation. Common catalysts include palladium(II) acetate in the presence of a phosphine ligand. The overall process is selective and yields a high purity product.

This compound is primarily used in the pharmaceutical industry for its potential therapeutic applications. It may also find use in the development of sensors and materials, particularly in the area of semiconductor technologies.

Proper personal protective equipment (PPE) such as gloves, goggles, and lab coats should be worn when handling this compound. It should be stored under inert conditions to avoid reactions with atmospheric moisture or gases. In case of spill, handle with care using appropriate spill containment materials and refer to the Safety Data Sheet (SDS) for specific instructions.